FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385647598> ?p ?o ?g. }

• W4385647598 endingPage "e657279e" @default.
• W4385647598 startingPage "e657279e" @default.
• W4385647598 abstract "Topic: 10. Myelodysplastic syndromes - Clinical Background: The transfusion burden differs among patients with lower-risk myelodysplastic syndrome (LR-MDS), and those receiving red blood cell (RBC) transfusions are at risk of iron overload. In such cases, the binding capacity of transferrin for iron is surpassed, resulting in non–transferrin-bound iron circulating in the blood and subsequent deposition of free iron in tissues, which can cause significant organ damage and is an important cause of morbidity and mortality. Although new agent such as luspatercept showed a notable response in transfusion-dependent patients with LR-MDS, many patients still need RBC transfusions. Therefore, determining the clinical outcomes of transfusion burden and optimizing treatment for patients with MDS with transfusion dependencies are important. Recently, the MDS International Working Group (IWG) has established criteria for transfusion dependence and defined three categories: non-transfusion-dependent (NTD), low transfusion burden (LTB), and high transfusion burden (HTB). Aims: This study retrospectively analyzed the prognostic impact of transfusion burden in patients with LR-MDS and the outcomes of each treatment option. Methods: Data on 168 patients with LR-MDS between July 2011 and April 2020 were retrospectively reviewed. Non-transfusion-dependent (NTD) was defined as no transfusion history in a period of 16 weeks, low transfusion burden (LTB) as receiving 3–7 red blood cell (RBC) units in a period of 16 weeks, and high transfusion burden (HTB) as receiving ≥8 RBC units in a period of 16 weeks. The treatment response was observed over 4–6 months after treatment. Results: Among the 168 patients, 105 were treated with anabolic steroids (n = 65), erythroid stimulating agents (n = 12), or hypomethylating agents (n = 28). The overall response rate was 53.3% (56/105), with 53 patients showing hematologic improvement (50.5%). The clinical benefit rate was 78.1% (82/105). The 5-year overall survival (OS) rates were 75.5%, 45.8%, and 33.3% for NTD, LTB, and HTB, respectively (p = 0.001). The 5-year incidence of acute myeloid leukemia were 0%, 9.9%, and 32.5% in NTD, LTB, and HTB, respectively (p < 0.001). In the multivariate analysis, age (hazard ratio [HR] 1.04, p = 0 009), LTB (HR 3.77, p = 0.002), HTB (HR 4.59, p < 0.001), and hemoglobin response (HR 0.45, p = 0.036) were significant factors for OS. Summary/Conclusion: Our findings show that transfusion dependency is an adverse prognostic factor in LR-MDS. Furthermore, HTB presented a higher risk of leukemic transformation.Keywords: Myelodysplastic syndrome, Transfusion, Prognostic factor" @default.
• W4385647598 created "2023-08-09" @default.
• W4385647598 creator A5010232519 @default.
• W4385647598 creator A5035694388 @default.
• W4385647598 creator A5036888293 @default.
• W4385647598 creator A5040333762 @default.
• W4385647598 creator A5068871430 @default.
• W4385647598 creator A5069793777 @default.
• W4385647598 creator A5076054253 @default.
• W4385647598 creator A5077318648 @default.
• W4385647598 creator A5089019336 @default.
• W4385647598 date "2023-08-01" @default.
• W4385647598 modified "2023-09-24" @default.
• W4385647598 title "PB2011: TRANSFUSION BURDEN IS AN IMPORTANT PROGNOSTIC FACTOR IN LOWER-RISK MYELODYSPLASTIC SYNDROME" @default.
• W4385647598 doi "https://doi.org/10.1097/01.hs9.0000974856.65727.9e" @default.
• W4385647598 hasPublicationYear "2023" @default.
• W4385647598 type Work @default.
• W4385647598 citedByCount "0" @default.
• W4385647598 crossrefType "journal-article" @default.
• W4385647598 hasAuthorship W4385647598A5010232519 @default.
• W4385647598 hasAuthorship W4385647598A5035694388 @default.
• W4385647598 hasAuthorship W4385647598A5036888293 @default.
• W4385647598 hasAuthorship W4385647598A5040333762 @default.
• W4385647598 hasAuthorship W4385647598A5068871430 @default.
• W4385647598 hasAuthorship W4385647598A5069793777 @default.
• W4385647598 hasAuthorship W4385647598A5076054253 @default.
• W4385647598 hasAuthorship W4385647598A5077318648 @default.
• W4385647598 hasAuthorship W4385647598A5089019336 @default.
• W4385647598 hasBestOaLocation W43856475981 @default.
• W4385647598 hasConcept C126322002 @default.
• W4385647598 hasConcept C177713679 @default.
• W4385647598 hasConcept C2780007613 @default.
• W4385647598 hasConcept C2780014101 @default.
• W4385647598 hasConcept C2780240888 @default.
• W4385647598 hasConcept C2780817109 @default.
• W4385647598 hasConcept C71924100 @default.
• W4385647598 hasConceptScore W4385647598C126322002 @default.
• W4385647598 hasConceptScore W4385647598C177713679 @default.
• W4385647598 hasConceptScore W4385647598C2780007613 @default.
• W4385647598 hasConceptScore W4385647598C2780014101 @default.
• W4385647598 hasConceptScore W4385647598C2780240888 @default.
• W4385647598 hasConceptScore W4385647598C2780817109 @default.
• W4385647598 hasConceptScore W4385647598C71924100 @default.
• W4385647598 hasIssue "S3" @default.
• W4385647598 hasLocation W43856475981 @default.
• W4385647598 hasLocation W43856475982 @default.
• W4385647598 hasOpenAccess W4385647598 @default.
• W4385647598 hasPrimaryLocation W43856475981 @default.
• W4385647598 hasRelatedWork W2064228685 @default.
• W4385647598 hasRelatedWork W2072525777 @default.
• W4385647598 hasRelatedWork W2090218255 @default.
• W4385647598 hasRelatedWork W2141612145 @default.
• W4385647598 hasRelatedWork W2324022207 @default.
• W4385647598 hasRelatedWork W2984147158 @default.
• W4385647598 hasRelatedWork W4223412214 @default.
• W4385647598 hasRelatedWork W4372257446 @default.
• W4385647598 hasRelatedWork W4379376395 @default.
• W4385647598 hasRelatedWork W4385647598 @default.
• W4385647598 hasVolume "7" @default.
• W4385647598 isParatext "false" @default.
• W4385647598 isRetracted "false" @default.
• W4385647598 workType "article" @default.